FDA Guide on Biosimilars
The FDA recently released a comprehensive guide on biosimilars and interchangeable biosimilars, emphasizing their safety, effectiveness, and potential to increase patient access to biologic medications. Here are the core points:
1. Definition and Similarity: Biosimilars are highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency. Interchangeable biosimilars can be substituted at the pharmacy without a prescriber’s intervention, depending on state laws.
2. Safety and Effectiveness: Both biosimilars and interchangeable biosimilars meet the same rigorous FDA standards as their reference products, ensuring equal safety and effectiveness.
3. Interchangeability: Not all biosimilars are interchangeable. Interchangeability requires a specific request and approval, influenced by factors like business strategy or the setting in which the drug is administered.
4. Prescription Confidence: Health care professionals can prescribe both biosimilars and interchangeable biosimilars with equal confidence, as both are equally safe and effective.
5. Increased Options: Biosimilars offer more treatment options and may reduce costs without compromising safety or effectiveness.
6. FDA Guidance Updates: The FDA is updating its guidance to streamline the approval process for interchangeable biosimilars based on accumulated experience, aiming for faster approvals while maintaining safety standards.
7. Public Health Impact: Biosimilars have significantly improved public health, offering nearly 700 million days of therapy, enhancing health equity, and increasing access to essential medications.
8. Purple Book Database: The FDA’s Purple Book Database provides comprehensive information on licensed biological products, including biosimilars, accessible to the public, healthcare professionals, and researchers.
9. Educational Resources: The FDA’s biosimilars website offers extensive educational materials, including fact sheets, videos, and a curriculum toolkit, available in multiple languages for both patients and healthcare professionals.
This guide underscores the FDA’s commitment to ensuring that biosimilars and interchangeable biosimilars are safe, effective, and accessible, ultimately benefiting public health by expanding treatment options and reducing costs.
For original article, browse through:
https://www.fda.gov/drugs/things-know-about/9-things-know-about-biosimilars-and-interchangeable-biosimilars
– S Kuppuswamy
